U.S. home-sale prices have declined for the third consecutive week, with the median price dropping 0.4% year over year to $388,604. This marks a shift after three years of rising prices, driven by slower demand and more cautious sellers, as new listings hit their lowest level since January. Mortgage payments also eased slightly due to falling rates and prices, giving buyers more negotiating power amid increased inventory and less competition. The market shows signs of balancing, with months of supply rising to 4.6, indicating a more even playing field between buyers and sellers.
U.S. home-sale prices have declined for the third consecutive week, with the median price down 0.4% year over year to $388,604, signaling easing market conditions. For readers following the Real Estate sector, here is Pluang's market snapshot as of Nov 05, 2026 20:11 WIB: out of 47 priced US Real Estate stocks, 33 rose and 14 fell today. Notable movers include IRM at USD 112.75 (-5.10%), JAN at USD 28.65 (-4.72%), and JLL at USD 375.30 (-3.85%) with a typical hold time of 72 days and a Pluang order activity skewed 70% Sell / 30% Buy.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
